Genmab — Earnings Release 2009

Feb 4, 2010

News Details

Ad-hoc | 4 February 2010 13:09

Arzerra 2009 Net Sales Figures

Genmab A/S /

04.02.2010

Dissemination of a Adhoc News, transmitted by
DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

---

Summary: Net sales of Arzerra? for the fourth quarter of 2009 were
approximately DKK 29 million, with an expected royalty payment to Genmab of DKK
6 million.

Copenhagen, Denmark; February 4, 2010 - Genmab A/S (OMX: GEN) announced today
that the U.S. net sales for Arzerra (ofatumumab) during the fourth quarter of
2009 were approximately DKK 29 million (approximately USD 5.5 million). Under
the terms of the collaboration with GlaxoSmithKline (GSK), Genmab expects to
receive a royalty payment of approximately DKK 6 million (approximately USD 1.1
million).

'We are very pleased to see the first sales figures for Arzerra and we believe
that they reflect the need for new treatment options for patients with
refractory CLL,' said Lisa N. Drakeman, Ph.D., Chief Executive Officer of
Genmab.

Arzerra was approved by the FDA in October, 2009, for the treatment of patients
in the U.S. with chronic lymphocytic leukemia (CLL) that is refractory to
fludarabine and alemtuzumab, and was launched by GSK in mid-November, 2009.

Arzerra is a monoclonal antibody that causes the body's immune response to
fight against normal and cancerous B-cells. Arzerra attaches to the small and
large loop epitopes - on a molecule called CD20, which is found on the surface
of B-cells, the type of cell that becomes cancerous in CLL.

About Genmab A/S
Genmab is a leading international biotechnology company focused on developing
fully human antibody therapeutics for the potential treatment of cancer.
Genmab's world class discovery and development teams are using cutting-edge
technology to create and develop products to address unmet medical needs. Our
primary goal is to improve the lives of patients who are in urgent need of new
treatment options. For more information on Genmab's products and technology,
visit www.genmab.com.

This Stock Exchange Release contains forward looking statements. The words
'believe', 'expect', 'anticipate', 'intend' and 'plan' and similar expressions
identify forward looking statements. Actual results or performance may differ
materially from any future results or performance expressed or implied by such
statements. The important factors that could cause our actual results or
performance to differ materially include, among others, risks associated with
product discovery and development, uncertainties related to the outcome and
conduct of clinical trials including unforeseen safety issues, uncertainties
related to product manufacturing, the lack of market acceptance of our
products, our inability to manage growth, the competitive environment in
relation to our business area and markets, our inability to attract and retain
suitably qualified personnel, the unenforceability or lack of protection of our
patents and proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our products obsolete,
and other factors. For a further discussion of these risks, please refer to the
section 'Risk Management' in Genmab's Annual Report, which is available on
www.genmab.com. Genmab does not undertake any obligation to update or revise
forward looking statements in this Stock Exchange Release nor to confirm such
statements in relation to actual results, unless required by law.

Genmab(r); the Y-shaped Genmab logo(r); HuMax(r); HuMax-CD20(r); HuMax-EGFr?;
HuMax-IL8?; HuMax-TAC?; HuMax-HepC?; HuMax-CD38?; HuMax-CD32b?; HuMax-TF?;
HuMax-Her2?; HuMax-VEGF? and UniBody(r) are all trademarks of Genmab A/S.
Arzerra? is a trademark of GlaxoSmithKline.

Contact: Helle Husted, Vice President, Investor Relations
T: +45 33 44 77 30; M: +45 25 27 47 13; E: h.husted@genmab.com

News Source: NASDAQ OMX

04.02.2010 Ad hoc announcement, Financial News and Media Release distributed by DGAP.
Media archive at www.dgap-medientreff.de and www.dgap.de

---

Language: English
Company: Genmab A/S

          Denmark

Phone:
Fax:
E-mail:
Internet:
ISIN: DK0010272202
WKN:

End of News DGAP News-Service

---